uniQure (NASDAQ:QURE – Get Rating) has received a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $59.31.
Several analysts have weighed in on QURE shares. Zacks Investment Research downgraded uniQure from a “buy” rating to a “hold” rating in a research note on Thursday, February 10th. William Blair started coverage on shares of uniQure in a report on Wednesday, October 27th. They issued an “outperform” rating and a $66.00 price target on the stock. Raymond James downgraded uniQure from a “strong-buy” rating to an “outperform” rating and lowered their target price for the stock from $75.00 to $58.00 in a research note on Thursday, December 16th. Finally, StockNews.com upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, February 5th.
In other uniQure news, Director Robert Gut sold 2,348 shares of the company’s stock in a transaction on Wednesday, January 26th. The stock was sold at an average price of $18.12, for a total transaction of $42,545.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Alexander Edward Kuta III sold 2,945 shares of the firm’s stock in a transaction on Wednesday, January 26th. The stock was sold at an average price of $18.02, for a total value of $53,068.90. The disclosure for this sale can be found here. Insiders have sold 26,157 shares of company stock worth $531,776 over the last ninety days. 2.66% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in uniQure by 1.2% during the 4th quarter. BlackRock Inc. now owns 4,293,805 shares of the biotechnology company’s stock worth $89,053,000 after buying an additional 50,307 shares during the period. Deutsche Bank AG boosted its holdings in uniQure by 27.4% in the fourth quarter. Deutsche Bank AG now owns 52,325 shares of the biotechnology company’s stock valued at $1,086,000 after purchasing an additional 11,250 shares during the period. California State Teachers Retirement System grew its stake in uniQure by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 29,283 shares of the biotechnology company’s stock worth $607,000 after purchasing an additional 1,077 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in uniQure by 16.0% during the 4th quarter. Parametric Portfolio Associates LLC now owns 77,671 shares of the biotechnology company’s stock worth $1,611,000 after purchasing an additional 10,685 shares during the period. Finally, State of Tennessee Treasury Department raised its position in uniQure by 10.2% in the 4th quarter. State of Tennessee Treasury Department now owns 22,680 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 2,100 shares in the last quarter. 78.95% of the stock is owned by institutional investors and hedge funds.
Shares of uniQure stock opened at $15.70 on Thursday. The company’s 50 day moving average is $18.83. The firm has a market cap of $725.56 million, a price-to-earnings ratio of 2.31 and a beta of 1.01. uniQure has a 12-month low of $15.59 and a 12-month high of $38.80. The company has a debt-to-equity ratio of 0.12, a current ratio of 14.16 and a quick ratio of 14.17.
About uniQure (Get Rating)
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.